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Editorial 
 
Withdrawal of treatment after devastating brain injury: 
post-cardiac arrest pathways lead in best practice 
 
 
Every year in England, cardiopulmonary resuscitation (CPR) is attempted on about 
30,000 people suffering an out of hospital cardiac arrest (OHCA) [1]. Return of 
spontaneous circulation (ROSC) is achieved in approximately 25%, and 7-8% of 
those in whom resuscitation is attempted will leave hospital alive. This figure is below 
the survival rates achieved in other countries, but if it could be increased to 10-11%, 
a further 1,000 lives a year could be saved in England [2]. The OHCA steering group 
aims to achieve this by addressing all aspects of the chain of survival pathway for 
victims of OHCA, and to this end has published its national framework “Resuscitation 
to Recovery” in March 2017 [1]. This single consensus document outlines a pathway 
based on best scientific evidence, national and international guidance, and expert 
opinion [3, 4]. Key elements of the framework are: to increase the number of patients 
who receive bystander CPR to more than the current 30-40% of all OHCA by 
increasing recognition of cardiac arrest; increasing the number of people trained in 
resuscitation; increasing the availability and use of public access defibrillators; 
transfer of patients who have achieved ROSC to recognised centres of care that 
provide immediate access to echocardiography, CT scanning, a cardiac 
catheterisation laboratory and advanced circulatory support techniques; 
management of post-resuscitation care in a general or cardiothoracic intensive care 
unit (ICU); and addressing the shortage of appropriate facilities for neurological and 
physical rehabilitation. 
 
One of the key recommendations made by the OHCA steering group is that 
neurological prognostication should not be made in the first 72 hours after ROSC, 
and for longer if hypothermia has been used as part of the intensive care 
management of the patient. This is already routine practice in UK ICUs; data from 
the Intensive Care National Audit and Research Centres (ICNARC) shows that 
between 2004 and 2014 the proportion of patients admitted to UK ICUs after OHCA 
increased from 9% to 12%, and that over this time both the length of stay in ICU and 
the time to the withdrawal of life-sustaining treatments (WLST) have also increased 
[5]. However, it is not that long ago that early neurological prognostication followed 
by withdrawal was common practice in patients admitted after OHCA. Over the past 
twenty years, the imprecision and inaccuracy of early prognostication after OHCA 
has been recognised, and this key recommendation to delay the WLST is supported 
by international resuscitation professional bodies [6-8]. The cardiac arrest community 
arguably leads the way in prognosticating after a severe neurological insult, in this 
case a hypoxic brain injury. If a patient remains comatose after allowing 72 hours for 
observation and physiological stabilisation, then using a combination of clinical 
examination (pupillary reactions, cough reflex, motor responses), radiology (CT or 
MRI brain), neurophysiology (electroencephalogram, somatosensory evoked 
potentials) and biomarkers (neurone specific enolase) may more precisely identify 
patients who will die or have a poor neurological outcome. While the ideal 
combination of tests needed for optimal prognostication remains unknown, 
cumulative experience with using these tools, coupled with careful audit, could lead 
to progressive refinement in the way we make decisions about WLST using objective 
scientific criteria. The importance of delaying prognostication and decisions to 
withdraw treatment is further emphasised by reports of 2.5% of OHCA survivors 
becoming responsive more than 7 days after rewarming [9]. The OHCA steering 
group stresses the importance of full discussions about withdrawal and its timing with 
the family, acknowledging the range of opinion about what constitutes an acceptable 
quality of life, and that some individuals or their families may be willing to accept 
survival with neurological disability. These opinions should be taken into 
consideration alongside the assessment of medical prognosis. The patient’s 
preferences and values should be elicited in discussions with the family and a 
shared decision-making approach used to develop a bespoke end-of-life care plan 
for the patient [10]. Finally, the steering group also made the point that when a 
decision to withdraw is made, it is important to consider organ donation and to offer 
this option to the family when it is a possibility. In 2014, 10% of patients dying after 
admission to UK ICUs following OHCA became solid organ donors compared with 
3% in 2004. [5]  
 
Is the approach to prognosticating after OHCA applicable to other areas of 
ICU practice? The Danish Nobel prize winning physicist Niels Bohr reputedly said 
that “prediction is very difficult, especially about the future”. This difficulty is clear 
when it comes to predicting the outcome of an individual patient receiving intensive 
care. When an individual member of the ICU team predicts that an ICU patient would 
not survive to hospital discharge, 50% of those predicted to die will nonetheless 
survive. When the ICU team unanimously predicts that the patient would not survive 
to hospital discharge,15% survive; and 12% survive even when the same prediction 
was made unanimously on 3 or more separate days of the patient’s ICU stay. [11]. 
These data underline the fact that individual assessments of outcome are less 
dependable than those that are shared across several members of the clinical team, 
but suggest that even assessments that are concordant across clinicians and over 
time have a finite error. These difficulties are likely to be exacerbated when trying to 
make early treatment limitation decisions based on predictions not just of mortality, 
but also on the anticipated future quality of life, which is a major consideration in 
patients with devastating brain injury and in as many as 50% of decisions to proceed 
to WLST in  ICU [12].  
 
There is concern that early withdrawal in the critically ill, especially those at 
the extreme end of the spectrum, such as comatose survivors of cardiac arrest, tend 
to be a self-fulfilling prophecy [13, 14]. Similar concerns have also been raised by the 
Neurocritical Care Society and neuro-intensive care opinion leaders about the early 
withdrawal in patients with devastating brain injury [15, 16]. Devastating brain injury 
can be defined as any neurological condition that is assessed at the time of hospital 
admission as an immediate threat to life or incompatible with good functional 
recovery and where early limitation or withdrawal of therapy is being considered. The 
Neurocritical Care Society strongly recommends using a 72-h period of physiological 
stabilisation and observation to determine the clinical response and delaying 
decisions regarding withdrawal in the meantime. This recommendation is gaining 
support from within both the UK ICU and Emergency Medicine communities [17, 18]. 
It is further supported by reports of unexpected survivors with good functional 
outcomes in patients admitted to ICU for a period of stabilisation and observation 
rather than undergoing early withdrawal [19] and by the observation that withdrawal 
is the most common cause of death in patients with DBI [15]. A forthcoming joint 
statement on the management of DBI from the Faculty of Intensive Care Medicine, 
the Intensive Care Society, the Society of British Neurological surgeons, the Royal 
College of Emergency Medicine and the Neuro Anaesthesia and Critical Care 
Society of Great Britain is also expected to recommend an approach that includes 
delaying withdrawal, physiological stabilisation, clinical observation and exclusion of 
confounding factors. 
 
Outcome studies, and the prediction models that are developed from them, only 
allow clinicians to provide a statistical likelihood of outcome, which can be applied to 
groups of devastating brain injury patients, but cannot provide satisfactory accuracy in 
individual cases [16]. Further, in relying on previously validated models of outcome 
prognostication, it should also be remembered that many patients in the studies 
underpinning these models would have died following treatment limitation decisions or 
the withdrawal. Including these data to predict outcome or to develop predictive 
models is flawed because they introduce a powerful bias and make prediction of 
mortality a self-fulfilling prophecy [20, 21]. Most prediction models are based on 
physiological data and radiological appearances at the time of hospital admission. 
Assessment of the patient’s response to stabilisation and active therapy not only 
increases the precision of prognostication, but also ensures that potential survivors do 
not undergo withdrawal inappropriately, and that the clinical outcome of any survivor 
is maximised [22]. Current outcomes may be better than those predicted by 
established prognostic schemes or by past experience might suggest, even for 
conditions that might be perceived to be devastating [23, 24]. For example, in one 
case series, favourable outcomes were obtained with intra-arterial therapy in 70% of 
patients with basilar artery occlusion treated more than 6 hours post-ictus [24], and 
patients with severe TBI who undergo decompressive craniectomy for intractable 
intracranial hypertension may experience late outcomes that are better than that 
predicted by well recognised prognostic schemes.[23] Finally, most prognostic 
schemes only provide a prediction of mortality, rather than functional outcome, a 
substantial failing when the quality of survival is considered more important than the 
duration of life by patients and their families [25].  
 
Delaying the decision to withdrawal to determine the clinical response will 
usually prove the initial prognosis correct, and can be undertaken as planned at this 
later stage after discussion within the multidisciplinary team. Other patients will 
continue to deteriorate and may fulfil the criteria to diagnose death using 
neurological criteria [26], which provides families with a conclusive diagnosis of 
death rather than a prognosis of a poor outcome. Finally, a few will improve [19], and 
the treatment plan can be reviewed by the multidisciplinary team. In most cases the 
clinical course of the patient becomes clear well before 72 hours, and the decision to 
withdraw, to test for the neurological determination of death, or to reverse the 
treatment limitations can be made at an earlier time [17, 19].  
 
The delay in withdrawal will not only increase prognostic accuracy but will also 
allow better shared decision making with the family, improve end of life care for the 
patient and their relatives, enable the incorporation of palliative care into the patient’s 
ICU management, and facilitate the adoption of best practice in organ donation [10, 
16, 17, 27-29].These are all good reasons for adopting pathways for the 
management of devastating brain injury that follow the principles of those for OHCA, 
but unfortunately there are no robust outcome studies for devastating brain injury 
pathways as there are for OHCA. It is essential that proper national audit of patients 
with devastating brain injury admitted to ICU are undertaken. National audit (for 
example, through ICNARC) is best placed to identify such patients and provide the 
data required for the development of rational protocols. Such audits must collect data 
that allows us to explore whether the pathways for non-OHCA devastating brain 
injury patients may require different details compared to those developed for OHCA. 
One key issue in this context includes decision making around time sensitive 
interventions such as evacuation of a space-occupying lesion, or 
thrombolysis/thrombectomy for occlusive cerebrovascular disease. Supporting 
systemic physiology while not attending to such primary pathology may fail to 
maximise the quality of outcome. Developing robust protocols to address this issue 
will not be easy, but where significant uncertainty of outcome exists in otherwise 
retrievable patients, there is a case for proceeding with definitive interventions as 
soon as systemic physiology is stabilised, and reassessing prognostic potential 
subsequently. A second issue will be the duration of observation that is needed for 
non-OHCA cases. While the current recommendation for OHCA is for a 72-hour 
window, this duration of observation may not be required in individuals where initial 
or follow up neuroimaging provides clear objective evidence of the extent and 
progress of neurological injury. 
 
Until such protocols are developed, it is not unreasonable that some ICU 
clinicians will continue to have reservations about devastating brain injury pathways. 
Some will be concerned that their use will increase the number of patients surviving 
with severe disability. This outcome is always a possibility when treating patients 
with severe brain injuries, even when they are being treated fully and aggressively. 
However, it must be remembered that the pathway does not remove the option to 
withdraw if a patient does not improve or continues to deteriorate; it simply delays 
that decision. Others will argue that good end of life care can be provided in many 
locations other than in the ICU. While this is true, tracheal extubation in patients with 
devastating brain injury in the emergency department not only removes any small 
hope of improvement, but gives families very little time to understand and come to 
terms with the situation. This does not mean that all patients with critical illness 
should be admitted to ICU for end of life care. Devastating brain injury is by its nature 
an unexpected and sudden onset illness, and unlike the families of patients known to 
have terminal illnesses such as metastatic malignancy or advanced dementia, 
families of patients admitted to the emergency department with devastating brain 
injury will have had little time for preparation for the potential death of a loved one.  
 
 Perhaps the greatest concern is that we have inadequate ICU resources, and 
that admitting patients with devastating brain injury will potentially deny these 
resources to patients with a better chance of survival. The pressure on ICU beds in 
the UK is relentless, and the practical, moral and financial impacts of increasingly 
using scarce ICU resources at the end of life are recognised [30]. These are 
concerns that have arisen previously with many patient populations, such as those 
with haematological malignancy, HIV, and neutropenic sepsis. These patients are 
now admitted routinely, with much improved outcomes. This argument would not sit 
comfortably with our current practice of routinely admitting patients after an OHCA 
despite only 7-8% of those receiving CPR surviving to hospital discharge [1]. Yet few 
would think that admitting these patients to ICU is an inappropriate use of ICU 
resources. Finally, the argument about resources goes beyond the individual ICU 
admitting the patient with devastating brain injury; the effect on wider NHS resources 
should also be considered. Clearly, where devastating brain injury occurs in a patient 
in whom severe comorbidities limit quality of life before the acute event, admission to 
ICU and further prolongation of clinical course would be inappropriate. Again, the 
collection of high-quality audit data would allow us to address implementations of 
different pathways for different contexts, based on clinical and community 
consensus. 
 
There will be views expressed that devastating brain injury pathways are 
being created simply to increase the potential for organ donation. The OHCA 
community already accept that organ donation is a positive secondary outcome of 
their pathways [5, 31]. Any increased organ donation potential following the 
introduction of these pathways should be viewed similarly. Indeed, one could 
question the equity of a situation where patients with devastating brain injury are only 
admitted to ICU, and in effect given a small chance of survival, if their relatives agree 
to organ donation, whereas patients whose family decline donation undergo 
withdrawal in the emergency department and are not given the same opportunity. 
Admitting a patient to the ICU for end-of-life care, and possibly organ donation, has 
been shown to yield on average seven times the quality-adjusted life years in 
transplant recipients per ICU bed-day compared with the average benefit for the 
admission of an ICU patient expected to survive [32]. Further, although an analysis of 
the relevant issues is complex [33], it is likely that the act of donation may provide 
some bereaved families benefit, especially when they feel that they are fulfilling the 
wishes of the potential donor, and when they feel that they have not been hurried 
into making a decision on donation.  
 
In conclusion, we believe that the time has come to develop rational pathways 
of care for the management of non-OHCA patients with devastating brain injury, 
which can draw on the considerable experience of managing these patients following 
OHCA. This would, in many cases, involve admitting patients with devastating brain 
injury to the ICU, stabilising systemic physiology and implementing time-sensitive 
definitive interventions where appropriate, and delaying withdrawal until the 
prognosis is clearer. This would ensure survival of retrievable patients, permit 
families time to come to terms with a catastrophic event, allow informed withdrawal 
after an appropriate interval, offer families the opportunity for carefully considered 
organ donation, and support development of the evidence base for clearer 
prognostication and decision making in the management of these patients. It is likely 
that uptake of these management principles is likely to vary between centres. Audit 
of such variations in practice could provide a substrate for observational comparative 
effectiveness research [34] in a context where formal randomised clinical trials may 
not currently be possible, and allow assessment of the benefits and costs of 
implementing these recommendations. 
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